Related references
Note: Only part of the references are listed.Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity
Kamini Krishnan et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Cerebrospinal Fluid A beta(42/40) Corresponds Better than A beta(42) to Amyloid PET in Alzheimer's Disease
Piotr Lewczuk et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Amyloid pet in primary progressive aphasia: case series and systematic review of the literature
Alberto Villarejo-Galende et al.
JOURNAL OF NEUROLOGY (2017)
18F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies
Jennifer L. Whitwell et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases
Sonja Daerr et al.
NEUROIMAGE-CLINICAL (2017)
Applied multimodal diagnostics in a case of presenile dementia
Sonja Schoenecker et al.
BMC NEUROLOGY (2016)
Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease
Solveig Tiepolt et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0
Satoshi Minoshima et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Clifford R. Jack et al.
NEUROLOGY (2016)
Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study
Marina Boccardi et al.
JAMA NEUROLOGY (2016)
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
Osama Sabri et al.
ALZHEIMERS & DEMENTIA (2015)
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis
Willemijn J. Jansen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Clinical, FDG and amyloid PET imaging in posterior cortical atrophy
Tarun D. Singh et al.
JOURNAL OF NEUROLOGY (2015)
Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease
Panagiotis Alexopoulos et al.
ALZHEIMERS & DEMENTIA (2014)
Practical utility of amyloid and FDG-PET in an academic dementia center
Pascual Sanchez-Juan et al.
NEUROLOGY (2014)
Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline
Michael Grundman et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2013)
Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association
Keith A. Johnson et al.
ALZHEIMERS & DEMENTIA (2013)
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease
Rik Vandenberghe et al.
NEUROIMAGE-CLINICAL (2013)
Amyloid imaging in dementias with atypical presentation
David A. Wolk et al.
ALZHEIMERS & DEMENTIA (2012)
Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges
Jonathan W. Bartlett et al.
BIOMARKERS IN MEDICINE (2012)
Added Diagnostic Value of 11C-PiB-PET in Memory Clinic Patients with Uncertain Diagnosis
K. S. Frederiksen et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA (2012)
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Katya Rascovsky et al.
BRAIN (2011)
Florbetaben to Trace Amyloid-beta in the Alzheimer Brain by Means of PET
Henryk Barthel et al.
JOURNAL OF ALZHEIMERS DISEASE (2011)
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study
Henryk Barthel et al.
LANCET NEUROLOGY (2011)
Classification of primary progressive aphasia and its variants
M. L. Gorno-Tempini et al.
NEUROLOGY (2011)
Pre-Clinical Detection of Alzheimer's Disease Using FDG-PET, with or without Amyloid Imaging
Lisa Mosconi et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Metabolite analysis of [18F]Florbetaben (BAY 94-9172) in human subjects: a substudy within a proof of mechanism clinical trial
M. Patt et al.
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY (2010)
Revising the definition of Alzheimer's disease: a new lexicon
Bruno Dubois et al.
LANCET NEUROLOGY (2010)
The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals
Bradford C. Dickerson et al.
CEREBRAL CORTEX (2009)
Worldwide variation in the doubling time of Alzheimer's disease incidence rates
Kathryn Ziegler-Graham et al.
ALZHEIMERS & DEMENTIA (2008)
Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias
Lisa Mosconi et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease
Norman L. Foster et al.
BRAIN (2007)
Mild cognitive impairment as a diagnostic entity
RC Petersen
JOURNAL OF INTERNAL MEDICINE (2004)
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study
A Drzezga et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Share Paper
